EyePoint Pharmaceuticals Inc
NASDAQ:EYPT

Watchlist Manager
EyePoint Pharmaceuticals Inc Logo
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
Watchlist
Price: 5.38 USD 12.08% Market Closed
Market Cap: 369.8m USD

EyePoint Pharmaceuticals Inc
Investor Relations

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2005-01-27. The Company’s lead product candidate, EYP-1901, combines a bioerodible formulation of its Durasert technology with vorolanib, a tyrosine kinase inhibitor (TKI), which has demonstrated anti-VEGF activity. The firm has two commercial products, YUTIQ and DEXYCU. YUTIQ is a non-erodible intravitreal implant containing fluocinolone acetonide (FA) lasting for up to 36 months and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ utilizes its Durasert sustained-release drug delivery technology platform. DEXYCU is an indicated for the treatment of post-operative ocular inflammation. DEXYCU utilizes its Verisome drug-delivery technology. The firm is also advancing YUTIQ 50, a six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the causes of blindness under a supplemental new drug application (sNDA) strategy.

Show more
Loading

Earnings Calls

2024 Q4
Jan 21, 2025
Show Transcript
Previous
Next
Fifth Third Bancorp shows strong growth and a positive outlook for 2025.
2024 Q4
Jan 21, 2025

In Q4 2024, Fifth Third Bancorp reported a strong earnings per share of $0.90 and achieved core adjusted pre-provision net revenue exceeding $1 billion for the first time in recent quarters. Revenue grew 2% year-over-year, supported by a 3% increase in loans. Looking ahead, the bank expects net interest income (NII) to rise 5-6% and average loans to increase by 3-4% in 2025. Shareholders saw $1.6 billion returned, including a $300 million share repurchase. With a robust balance sheet and strategic branch expansion, Fifth Third is well-positioned for growth amidst changing market dynamics.

Show Full Analysis

Management

Dr. Jay S. Duker M.D.
President, CEO & Director
No Bio Available
Mr. George O. Elston CPA
Executive VP & CFO
No Bio Available
Dr. John B. Landis M.S., Ph.D.
Interim Head of R&D and Director
No Bio Available
Mr. Michael J. Maciocio
Senior Vice President of Manufacturing & Operations
No Bio Available
Mr. Ron I. Honig Esq.
Chief Legal Officer & Company Secretary
No Bio Available
Ms. Jennifer Leonard
Chief People Officer & Senior VP of IT
No Bio Available
Mr. David Scott Jones M.A.
Senior VP & Chief Commercial Officer
No Bio Available
Mr. Michael Pine
Chief Business Officer
No Bio Available
Ms. Isabelle Lefebvre
Chief Regulatory Officer
No Bio Available
Dr. Marcia Sellos-Moura Ph.D.
Senior VP and Head of Development & Program Management
No Bio Available

Contacts

Address
MASSACHUSETTS
Watertown
480 Pleasant St Ste B300
Contacts
+16179265000.0
eyepointpharma.com